Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sitagliptin + metformin (Scotmann Pharmaceuticals)
- Development stage
- Phase 4
- Lead developer
- Scotmann Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Trapeze Plus is a fixed-dose combination medication containing sitagliptin and metformin, developed by Scotmann Pharmaceuticals for the management of type 2 diabetes mellitus. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the body's natural ability to lower blood sugar by increasing levels of incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner. Metformin is a biguanide that reduces hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Together, these agents provide complementary mechanisms to improve glycemic control in patients with type 2 diabetes. Trapeze Plus is available in both immediate-release and extended-release (Trapeze Plus XR) formulations.
- Brand names
- Trapeze PlusTrapeze Plus XR
- Other names
- Sitagliptin and Metformin
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)DPP-4 (Dipeptidyl Peptidase-IV)ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on sitagliptin + metformin (Scotmann Pharmaceuticals).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sitagliptin + metformin (Scotmann Pharmaceuticals).